(IN BRIEF) Researchers from the Brain Repair laboratory at the University of Helsinki have investigated whether a protein called cerebral dopamine neurotrophic factor (CDNF) has potential as a treatment for intracerebral haemorrhage, a condition where bleeding into brain tissue causes … Read the full press release
Posted in Education, Finland, Healthcare, Management, News, Pharma & Biotech, Science
Tagged brain hemorrhage, cerebral dopamine neurotrophic factor (CDNF), Dr. Vassileios Stratoulias, intracerebral haemorrhage, Mikko Airavaara, Parkinson's disease, protein, protein therapy, researchers, treatment, University of Helsinki
Application is being reviewed under the US FDA’s Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive early-stage lung cancer, compared with … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged atezolizumab, Cancer Immunotherapy, chemotherapy, FDA, Levi Garraway, lung cancer, non-small cell lung cancer, NSCLC, Real-Time Oncology Review, Roche, sBLA, supplemental Biologics License Application, Tecentriq®, treatment, tumours
BASEL, 18-Jul-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Avastin, carcinoma, FDA, Roche, Sandra Horning, TECENTRIQ, treatment
The UK has today (Monday 19 March) signed the European X-Ray Free-Electron Laser (XFEL) convention in Berlin, Germany. UK signs agreement to work with other countries to create new medical treatments using a powerful laser super-strength laser acts like a microscope … Read the full press release
Posted in Government, Law, Science, Technology, United Kingdom
Tagged European X-Ray Free-Electron Laser convention, laser, microscope, Sam Gyimah, treatment, viruses, XFEL, XFEL convention
Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. QIDP status provides priority review and … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Switzerland
Tagged Barbara Zink, Basilea Pharmaceutica, fungal infections, invasive aspergillosis, Isavuconazole, isavuconazonium sulfate, Peer Nils Schröder, QIDP, Qualified Infectious Disease Product, Ronald Scott, treatment, U.S. FDA, zygomycosis
23-4-2013 — /europawire.eu/ — These sorts of new techniques potentially offer exciting possibilities to patients for the treatment of a range of difficult or previously untreatable conditions. Like all treatments, these techniques also come with benefits and risks. Specific rules were introduced … Read the full press release
Posted in European Union, Government, Healthcare, Law, Pharma & Biotech, Society, United Kingdom
Tagged EMA, European Medicines Agency, medicines, patients, Stem cell, Stem cell therapy, Stem cell therapy treatments, therapy, traceability of materials, treatment, treatment protocols, untreatable conditions
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?